Novartis AG (NYSE:NVS) Receiving Somewhat Favorable News Coverage, Accern Reports
Headlines about Novartis AG (NYSE:NVS) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Novartis AG earned a news impact score of 0.20 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.160371557505 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern’s rankings:
- Novartis AG (NVS) Upgraded by BidaskClub to “Hold” (americanbankingnews.com)
- Healthcare Ticker: Quick Roundup of Gainers and Losers, Aug. 4 (fxpips.com)
- Gilead Could Be Making An Acquisition — But It's Not What You Think (finance.yahoo.com)
- United Therapeutics stock up 9 percent on GSK acquisition report (finance.yahoo.com)
- Analysts Set Novartis AG (NYSE:NVS) Target Price at $80.94 (bulhufas.com)
NVS has been the topic of a number of recent research reports. Zacks Investment Research downgraded Novartis AG from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Credit Suisse Group downgraded Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 price target for the company. in a research note on Wednesday, July 5th. Morgan Stanley upgraded Novartis AG from an “underweight” rating to an “overweight” rating in a research note on Wednesday, July 26th. Leerink Swann reiterated a “market perform” rating and set a $83.00 price target on shares of Novartis AG in a research note on Thursday, June 22nd. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research note on Tuesday, April 18th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $81.71.
Novartis AG (NYSE:NVS) traded up 0.02% during trading on Wednesday, hitting $84.18. The company had a trading volume of 1,582,409 shares. The stock has a market capitalization of $197.22 billion, a PE ratio of 30.73 and a beta of 0.73. The stock has a 50-day moving average of $83.98 and a 200-day moving average of $78.22. Novartis AG has a one year low of $66.93 and a one year high of $86.90.
Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. During the same quarter in the previous year, the company posted $1.23 earnings per share. The business’s revenue was down 1.8% on a year-over-year basis. On average, equities analysts anticipate that Novartis AG will post $4.75 EPS for the current year.
In other news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of Novartis AG stock in a transaction dated Wednesday, July 5th. The stock was bought at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.01% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/09/novartis-ag-nysenvs-receiving-somewhat-favorable-news-coverage-accern-reports.html.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.